Keywords: hollis-eden, advances, potential, first-in-class, drugs, into, mid-stage
Hollis-Eden advances two potential first-in-class drugs into mid-stage testing
Article | 18 August 2008
US drug developer Hollis-Eden Pharmaceuticals says that it made strong progress in the second quarter of 2008, advancing two clinical development ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
